Next week, DDI expert Dr. Brian Ogilvie will be discussing the impacts of the newly finalized ICH M12 on #invitro #druginteractions study design and interpretation. The Guideline replaces corresponding guidance documents from the US FDA, EMA, and PMDA, among others. Make sure your studies meet these new regulatory expectations – learn more and register now: https://hubs.ly/Q02GxZFD0 #ADME #DMPK #DrugMetabolism #Enzymes #DrugTransporters
About us
BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease state samples including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our Research Services team works collaboratively with clients to provide in vitro hepatic modeling solutions. And as the world’s premier supplier of ADME-Tox model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®.
- Website
-
http://www.bioivt.com/
External link for BioIVT
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Hicksville, NY
- Type
- Privately Held
- Specialties
- Human and Animal Biologicals of the highest quality, Customized for every individual order, High level of customer service, Products delivered in a timely matter, ready for use, and Unconditional product guarantee
Locations
-
Primary
Post Office Box 770
Hicksville, NY 11802, US
Employees at BioIVT
Updates
-
The condition of cells can have a big impact on your research. Understanding the relationship between temperature, time, and the stability of immune cell populations in #leukopaks is critical for maximizing the potential of human peripheral blood mononuclear cells (#PBMCs) in your #CellandGeneTherapy research. Read the whitepaper discussing our ASGCT 2024 poster for an in-depth look at cell viability following fresh leukapheresis under different simulated shipping conditions for insights that can help you define your approach to cell transport and preservation: https://lnkd.in/eVQKP_wD #CellTherapy #GeneTherapy #Biospecimens
-
New collaborative #scientificposter on #lysosomes presented this week at the GRC Drug Metabolism Conference: https://lnkd.in/eb9rrbDP Understanding the distribution and abundance of #drugtargets, metabolizing #enzymes, and #drugtransporters within liver subcellular compartments is crucial for #drugmetabolism and #toxicity studies. This study focused on identification and quantification using global quantitative #proteomics analysis.
Human liver lysosomes Biologics entering the cells by receptor-mediated uptake, e.g., antibody drug conjugates and related targeted modalities, are processed in the vesicles of endosomal-lysosomal pathway and can be catabolized in lysosomes. Specific metabolic reactions performed by lysosomal enzymes are essential for proper release and pharmacological activity of biologic’s payloads. In their catabolic capacity lysosomal enzymes act as a “microsomes for biologics”. Plurality of hydrolases contained in human liver lysosomes is scarcely characterized for metabolic activity, abundance, and regulation. Similarly, variability of these enzymes in individual donors and multiple organs has not been characterized. Dr. Prasad Research Group (https://pharmacy.wsu.edu/) provided proteomic characterization of BioIVT human liver lysosomes (HLL) from 15 donors (https://lnkd.in/gMgGSHTQ). Major findings of the work, presented this week at Gordon Research Conference (https://lnkd.in/gTdsdMBb) are 1) lysosomal markers (e.g., HEXA, HEXB, ACP2, and GUSB) are highly enriched and abundant in lysosomal preparation but not detected in human liver microsomes, 2) endoplasmic reticulum markers and mitochondrial markers are also detected in the lysosomal reparations, 3) multiple drug metabolizing enzymes and transporters are also enriched in HLL. These data enable proper design and interpretation of results of studies elucidating catabolism of biologics in lysosomes.
-
-
We understand your molecule is going through a unique journey, not only through the #drugdevelopment pipeline but also through the patient. BioIVT serves as a guide on this journey, helping you navigate the right path and understand the steps along the way. We can provide #biospecimens and #contractresearch services specific to your needs to help you understand your compound’s #ADME properties and risk of #DrugInteractions so you can avoid costly pitfalls such as late-stage failure and regulatory roadblocks. Our goal is to arm you with reliable, defendable data, and our in-house experts have been around long enough to understand regulatory expectations and to help you solve unique challenges. Let BioIVT be your resource—for test systems, services, consultancy, or field-specific scientific content—we have it all: https://hubs.ly/Q02FyQqV0
-
#LiquidBiopsy researchers are exploring a wide range of #biomarkers to offer insights into disease presence, prognosis, treatment response, and earlier minimal residual disease detection. However, pre-analytical variables can have a big influence on their results. Watch our on-demand webinar with Courtney Noah, PhD to learn about ways to improve clinical accuracy, reproducibility, and patient impact ➡️ https://lnkd.in/gzZjY3mB #MolecularTesting #Diagnostics #CancerResearch
-
Register to hear #DrugInteractions expert, Dr. Brian Ogilvie, outline changes to the in vitro sections of the new ICH M12 Guideline and compare it with previous guidance, including equations and cutoff values as well as experimental details ➡️ https://hubs.ly/Q02FyS5h0 #ADME #DMPK #DrugMetabolism #Enzymes #DrugTransporters
LIVE Webinar: Highlights From the Final ICH M12 Guideline “Drug Interaction Studies” — What’s changed and considerations for your IND programs
info.bioivt.com
-
Choosing the right cellular starting and raw materials vendor for your #CellandGeneTherapy program is crucial. Discover three key strategies to evaluate and find the perfect fit. Download our full guide to learn more and make an informed decision for your #ATMPs ➡️ https://lnkd.in/g9nBWSuv #CellTherapy #GeneTherapy #AdvancedTherapies #QualityControl #VendorSelection
-
Make sure to catch Tina Mueller, PhD’s #scientificposter on Wed. and Thurs. from 4-6pm at the Gordon Research Conferences (#GRC) #DrugMetabolism Conference (https://hubs.ly/Q02FyT9s0) looking at the results from over 400 sponsored reaction phenotyping studies to assess whether drugs in #preclinical development have shown a potential shift towards non-CYP metabolism. Since most approved drugs are metabolized by CYP #enzymes, thereby increasing the risk for #druginteractions, it’s been speculated that non-CYP metabolism might become more prominent. However, no such trend has been observed for approved drugs, so we looked to see whether there has been an increase of non-CYP reaction phenotyping studies showing the involvement of non-CYP enzymes compared to approved drugs. #GordonResearchConferences #ADME #DMPK
-
-
Imola Juhász, PhD and Ji Young Lee, PhD are available at the 25th International Symposium on Microsomes and Drug Oxidations (MDO) to help you find the right #biospecimens or #ADME research services for your program. Make sure to stop by or connect! ➡️ View our extensive test system options: https://hubs.ly/Q02DTp360 ➡️ Explore our expert research services: https://hubs.ly/Q02DThCV0 #MDOPRAGUE2024 #Microsomes #Hepatocytes #Enzymes #DrugMetabolism #DrugInteractions
-